Skip to main content
SpringerLink
Log in

Treatment of Parkinson’s Disease

  • Chapter
  • First Online:
Techniques for Assessment of Parkinsonism for Diagnosis and Rehabilitation

Part of the book series: Series in BioEngineering ((SERBIOENG))

Abstract

Treatment of Parkinson’s disease (PD) is based on the principle that the deficiency of dopamine in the brain can be countered by administering its natural precursor (levodopa). Apart from this we discussed other oral therapies which can be commenced as monotherapy or adjunctive therapies including MAO-B Inhibitors, COMT Inhibitors, NMDA receptor antagonist, Adenosine A2A receptor antagonist and Dopamine agonists. We explained the rationale of early treatment, strategy of initial treatment, the significance of continuous dopaminergic stimulation, strategy of treatment for advanced PD, and deep brain stimulation as a surgical treatment. We also discussed the side effects and other issues arising from administration of various therapies. We compared various device assisted therapies especially in advanced PD cases and tried to shed some light on choice of each of them under various circumstances. We touch based newer therapies and strategies which are still under investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Olanow, C.W., Watts, R.L., Koller, W.C.: An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 56(11Suppl 5), S1-S88 (2001)

    Google Scholar 

  2. Olanow, C.W., Stern, M.B., Sethi, K.: The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72(Suppl 4), S1–S136 (2009)

    Article  Google Scholar 

  3. Fox, S.H., Katzenschlager, R., Lim, S.-Y., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C.G., Sampaio, C.: The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov. Disord. 26(S3), 1–414 (2011)

    Article  Google Scholar 

  4. Fox, S.H., Katzenschlager, R., Lim, S.-Y., Barton, B., de Bie, R.M.A., Seppi, K., Coelho, M., Sampaio, C.: On behalf of the movement disorder society evidence-based medicine committee. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord.33(8), 1246–1266 (2018)

    Google Scholar 

  5. Hauser, R.A., Auinger, P., Oakes, D.: Levodopa response in early Parkinson’s disease. Mov. Disord. 24(16), 2328–2336 (2009)

    Article  Google Scholar 

  6. Antonini, A., Fung, V.S.C., Boyd, J.T., Slevin, J.T., Hall, C., Chatamra, K., Eaton, S., Benesh, J.A.: Effect of Levodopa-Carbidopa Intestinal Gel on Dyskinesia in advanced Parkinson’s disease patients. Mov. Disord. 31(4), 530–537 (2016)

    Article  Google Scholar 

  7. Chen, J.J., Swope, D.M.: Pharmac. Parkinson’s Dis. Pharmac. 27(12 Pt 2), 161S-173S (2007)

    Google Scholar 

  8. Hayes, M.W., Fung, V.Sc., Kimber, T.E., O'Sullivan, J.D.: Updates and advances in the treatment of Parkinson disease. Med. J. Aust. 211(6), 277–283 (2019)

    Google Scholar 

  9. Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., Lees, A.J.: Parkinson's disease research group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 12; 71(7), 474–480 (2008)

    Google Scholar 

  10. LeWitt, P.A., Fahn, S.: Levodopa therapy for Parkinson disease: table. Neurology 86(14 Suppl 1), S3–S12 (2016)

    Article  Google Scholar 

  11. Holford, N., Nutt, J.G.: Disease progression, drug action and Parkinson’s disease: why time cannot be ignored. Eur. J. Clin. Pharmacol. 64(2), 207–216 (2008)

    Google Scholar 

  12. PD Med Collaborative Group.: Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet Sep. 27. 384(9949), 1196–1205. doi: https://doi.org/10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Erratum in: Lancet. 2014 Sep 27, 384(9949), 1186. PMID: 24928805 (2014)

  13. Clarke, C.E.: Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov. Disord. 10(3), 250–256 (1995)

    Article  Google Scholar 

  14. Sharma, J.C., Ross, I.N., Rascol, O., Brooks, D.: Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur. J. Neurol. 15, 493–496 (2008)

    Article  Google Scholar 

  15. Olanow, C.W., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A.H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F.: for the Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) Investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov. Disord.8, 1064–1071 (2013)

    Google Scholar 

  16. Dietrichs, E., Odin, P.: Algorithms for the treatment of motor problems in Parkinson’s disease. Acta. Neurol. Scand. 136, 378–385 (2017)

    Article  Google Scholar 

  17. Koller, W.C., Hutton, J.T., Tolosa, E., Capilldeo, R.: and the Carbidopa/Levodopa Study Group*. Immediate-release and controlled-release carbidopa/levodopa in PD A 5-year randomized multicenter study. Neurology 53, 1012–1019 (1999)

    Google Scholar 

  18. Stocchi, F., Rascol, O., Kieburtz, K., Poewe, W., Jankovic, J., Tolosa, E., Barone, P., Lang, A.E., Olanow, C.W.: Initiating Levodopa/Carbidopa therapy with and without entacapone in early parkinson disease The STRIDE-PD study. Ann. Neurol. 68, 18–27 (2010)

    Article  Google Scholar 

  19. Dhall, R., Kreitzman, D.L.: Advances in levodopa therapy for Parkinson disease review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology 86(Suppl 1), S13–S24 (2016)

    Google Scholar 

  20. LeWitt, P.A., Hauser, R.A., Pahwa, R., Isaacson, S.H., Fernandez, H.H., Lew, M., Saint-Hilaire, M., Pourcher, E., Lopez-Manzanares, L., Waters, C., Rudzínska, M., Sedkov, A., Batycky, R., Oh, C.: Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 18(2), 145–154 (2019). https://doi.org/10.1016/s1474-4422(18)30405-8)

    Article  Google Scholar 

  21. Radad, K., Gille, G., Rausch, W.D.: Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol. Rep. 57(6), 701–712 (2005)

    Google Scholar 

  22. Lange, K.W.: Clinical pharmacology of dopamine agonists in Parkinson’s disease. Drugs Aging. 13(5), 381–389 (1998)

    Article  Google Scholar 

  23. Antonini, A., Barone, P.: Dopamine agonist-based strategies in the treatment of Parkinson’s disease. Neurol. Sci. 29, S371–S374 (2008)

    Article  Google Scholar 

  24. Tolosa, E., Horstink, M.: Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European federation of neurological societies and the movement disorder society-European section. Part I: early (uncomplicated) Parkinson’s disease. Eur. J. Neurol. 13, 1170–1185 (2006)

    Article  Google Scholar 

  25. Ahlskog, J.E., Uitti, R.J.: Rasagiline, Parkinson neuroprotection, and delayed-start trials still no satisfaction? Neurology 74, 1143–1148 (2010)

    Article  Google Scholar 

  26. Fabbri, M., Rosa, M.M., Abreu, D., Ferreira, J.J.: Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener Dis. Manag. 5, 481–496 (2015)

    Article  Google Scholar 

  27. Murata, M., Hasegawa, K., Kanazawa, I., Fukasaka, J., Kochi, K., Shimazu, R.: Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study. Mov. Disord. 30, 1343–1350 (2015)

    Article  Google Scholar 

  28. Rinne, U.K., Larsen, J.P., Siden, A., Worm-Petersen, J.: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt. Study Group. Neurol. 51, 1309–1314 (1998)

    Google Scholar 

  29. Fabbri, M., Ferreira, J.J., Lees, A., Stocchi, F., Poewe, W., Tolosa, E., Rascol, O.: Opicapone for the treatment of Parkinson’s disease: a review of a new licensed medicine. Mov. Disord. 33(10), 1528–1539 (2018)

    Article  Google Scholar 

  30. Pahwa, R., Tanner, C.M., Hauser, R.A., Sethi, K., Isaacson, S., Truong, D., Struck, L., Ruby, A.E., McClure, N.L., Went, G.T., Stempien, M.L.: Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study). Mov. Disord. 30(6), 788–795 (2015)

    Google Scholar 

  31. Oertel, W., Eggert, K., Pahwa, R., Tanner, C.M., Hauser, R.A., Trenkwalder, C., Ehret, R., Azulay, J.P., Isaacson, S., Felt, L., Stempien, M.J.: Randomized, Placebo-controlled trial of ADS-5102 (Amantadine) extended-release capsules for levodopa-induced Dyskinesia in Parkinson’s disease (EASE LID 3). Mov. Disord 32(12), 1701–1709 (2017)

    Article  Google Scholar 

  32. Vorovenci, R.J., Antonini, A.: The efficacy of oral adenosine A2A antagonist is tradefylline for the treatment of moderate to severe Parkinson’s disease. Expert Rev. Neurother 15(12), 1383–1390 (2015)

    Article  Google Scholar 

  33. Krack, P., Volkmann, J., Tinkhauser, G., Deuschl, G.: Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov. Disord. 34(12), 1795–1810 (2019)

    Article  Google Scholar 

  34. Krack, P., Martinez-Fernandez, R., Del Alamo, M., Obeso, J.A.: Current applications and limitations of surgical treatments for movement disorders. Mov. Disord. 32(1), 36–52.28 (2017)

    Google Scholar 

  35. Castrioto, A., Lozano, A.M., Poon, Y.-Y., Lang, A.E., Fallis, M., Moro, E.: Ten-year outcome of subthalamic stimulation in Parkinson disease a blinded evaluation. Arch Neurol. 68(12), 1550–1556 (2011)

    Article  Google Scholar 

  36. Schuepbach, W.M.M., Tonder, L., Schnitzler, A., Krack, P., Rau, J., Hartmann, A., Halbig, T.D., Pineau, F., Falk, A., Paschen, L., Paschen, S., Volkmann, J., Dafsari, H.S., Barbe, M.T., Fink, G.R., Kuhn, A., Kupsch, A., Schneider, G.-H., Seigneuret, E., Fraix, V., Kistner, A., Chaynes, P.P., Ory-Magne, F., Brefel-Courbon, C., Vesper, J., Wojtecki, L., Derrey, S., Maltete, D., Damier, P., Derkinderen, P., Sixel-Doring, F., Trenkwalder, C., Gharabaghi, A., Wachter, T., Weiss, D., Pinsker, M.O., Regis, J.-M., Witjas, T., Thobois, S., Mertens, P., Knudsen, K., Schade-Brittinger, C., Houeto, J.-L., Agid, Y., Vidailhet, M., Timmermann, L., Deuschl, G., for the EARLYSTIM study group, : Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology 92, e1109–e1120 (2019)

    Article  Google Scholar 

  37. Engel, K., Huckhagel, T., Gulberti, A., Pötter-Nerger, M., Vettorazzi, E., Hidding, U. et al.: Towards unambiguous reporting of complications related to deep brain stimulation surgery: a retrospective single-center analysis and systematic review of the literature. PLoS One 13(8), e0198529 (2018)

    Google Scholar 

  38. Weintraub, D., Duda, J.E., Carlson, Luo, P., Sagher, O., Stern, M., Follett, K.A., Reda, D., Weaver, F.M.: for the CSP 468 Study Group et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson’s disease: results from a randomised, controlled trial. J. Neurol. Neurosurg. Psyc. 84(10), 1113–1118 (2013)

    Google Scholar 

  39. di Biase, L., Fasano, A.: Low-frequency deep brain stimulation for Parkinson’s disease: great expectation or false hope? Mov. Disord. 31(7), 962–967 (2016)

    Article  Google Scholar 

  40. Antonini, A., Moro, E., Godeiro, C., Reichmann, H.: Medical and surgical management of advanced Parkinson’s disease. Mov. Disord. 33(6), 900–908 (2018)

    Article  Google Scholar 

  41. Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C., Deuschl, G., Chaudhuri, R., Henriksen, T., van Laar, T., Spivey, K., Vel, S., Lees, A.: Double-blind, randomized, placebo-controlled, phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing ‘OFF’ time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized medical treatment. Mov. Disord. 32(Suppl 2), S518–S519 (2017)

    Google Scholar 

  42. Hauser, R.A., Olanow, C.W., Dzyngel, B., Bilbault, T., Shill, H., Isaacson, S., Dubow, J., Agro, A.: Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov. Disord. 31(9), 1366–1372 (2016)

    Article  Google Scholar 

  43. Antonini, A., Poewe, W., Chaudhuri, K.R., Jech, R., Pickut, B., Pirtosek, Z., Szasz, J., Valldeoriola, F., Winkler, C., Bergmann, L., Yegin, A., Onuk, K., Barch, D., Odin, P.: on behalf of the GLORIA study co-investigators. Suitable for LCIG are APD patients with response to L-dopa, severe motor fluctuations and hyper-/dyskinesia, when the combination of oral drugs has not given satisfactory results. Parkinsonism Relat. Disord. 45, 13–20 (2017)

    Google Scholar 

  44. Devigili, G., Rinaldo, S., Lettieri, C., Eleopra, R.: Levodopa/carbidopa intestinal gel therapy for advanced Parkinson disease: an early toxic effect for small nerve fibers? SFN and L-Dopa Gel Therapy. Muscle. Nerve. 54, 970–972 (2016)

    Article  Google Scholar 

  45. Odin, P., Ray Chaudhuri, K., Slevin, J.T., Volkmann, J., Dietrichs, E., Martinez-Martin, P., Krause, J.K., Henriksen, T., Katzenschlager, R., AntoniniA, R.O., Poeve, W.: Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat. Disord. 21, 1133–1144 (2015)

    Article  Google Scholar 

  46. Pahwa, R., Factor, S.A., Lyons, K.E., Ondo, W.G., Gronseth, G., Bronte-Stewart, H., Hallet, M., Miyasaki, J., Stevens, J., Weiner, W.J.: Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 66, 983–995 (2006)

    Article  Google Scholar 

  47. Olanow, C.W., Kieburtz, K., Odin, P., Espay, A.J., Standaert, D.G., Fernandez, H.H., Vanagunas, A., Othman, A.A., Widnell, K.L., Robieson, W.Z., Pritchett, Y., Chatamra, K., Benesh, J., Lenz, R.A., Antonini, A., LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13, 141–149 (2014)

    Google Scholar 

  48. Antonini, A., Isaias, I.U., Rodolfi, G., Landi, A., Natuzzi, F., Siri, C., Pezzoli, G.: A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J. Neurol. 258, 579–585 (2011)

    Google Scholar 

  49. Deuschl, G., Agid, Y.: Subthalamic neurostimulation for Parkinson’s disease with early fluctuations: balancing the risks and benefits. Lancet Neurol. 12, 1025–1034 (2013)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Engineering, RMIT University, Melbourne, VIC, Australia

    Sanjay Raghav

  2. Department of Neuroscience, Monash Health, Melbourne, VIC, Australia

    Sanjay Raghav & Laura D. Perju-Dumbrava

Authors
  1. Sanjay Raghav
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura D. Perju-Dumbrava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjay Raghav .

Editor information

Editors and Affiliations

  1. Department of Electronics and Instrumentation Engineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India

    Sridhar P. Arjunan

  2. Biosignals lab, School of Engineering, RMIT University, Melbourne, VIC, Australia

    Dinesh Kant Kumar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Raghav, S., Perju-Dumbrava, L.D. (2022). Treatment of Parkinson’s Disease. In: Arjunan, S.P., Kumar, D.K. (eds) Techniques for Assessment of Parkinsonism for Diagnosis and Rehabilitation. Series in BioEngineering. Springer, Singapore. https://doi.org/10.1007/978-981-16-3056-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-3056-9_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-3055-2

  • Online ISBN: 978-981-16-3056-9

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation